Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 9;11(8):1194. doi: 10.3390/biology11081194

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

sFlt-1 in the serum from AMI patients inhibits the angiogenesis of EPCs. (A) The ability of AMI patients’ serum to inhibit the angiogenesis of EPCs. Control, EPCs cultured in serum-free medium; normal, EPCs cultured in medium containing serum from healthy subjects; MI-1/MI-2/MI-3, EPCs cultured in medium containing serum from different AMI patients. (B) ELISA assay of VEGF and sFlt-1 in serum from AMI patients and healthy subjects. Data are shown as the mean ± SEM; * p < 0.05, ns, not significant. (C) Effect of VEGF and sFlt-1 on the angiogenesis of EPCs.